Verge Genomics

Verge Genomics is a private, clinical-stage biotech leveraging a proprietary AI platform, CONVERGE®, to discover and develop novel therapeutics. The company's lead program, VRG50635, a PIKfyve inhibitor for ALS, is in Phase 1, marking a key milestone of discovering a novel target and developing a clinical candidate entirely in-house. With a pipeline spanning neuroscience, metabolic, and immunology indications, Verge aims to address diseases with complex biology and high unmet need. The company is led by a team combining drug development expertise with technology leadership.

CONVERGE®: An all-in-human, AI-powered drug discovery platform that uses a proprietary multi-omics database from human tissue and machine learning to map complex disease biology, identify novel targets, and develop drug candidates internally.

Verge competes with other AI-driven biotechs (e.g., Recursion, Exscientia, Insitro) and traditional neuroscience-focused pharma. Its key differentiator is the 'all-in-human' data foundation and full internal integration from target discovery to clinical candidate, unlike many AI companies that focus on target identification or drug design alone.